Insulin-like peptide 5 (INSL5) is a peptide that belongs to the relaxin/insulin family, and its receptor has not been identified. In this report, we demonstrate that INSL5 is a specific agonist for GPCR142. Human INSL5 displaces the binding of 125I-relaxin-3 to GPCR142 with a high affinity (Ki = 1.5 nm). In a saturation binding assay, 125I-INSL5 binds GPCR142 with a Kd value of 2.5 nm. In functional guanosine (γ-thio)-triphosphate binding and cAMP accumulation assays, INSL5 potently activates GPCR142 with EC50 values of 1.3 and 1.2 nm, respectively. In addition, INSL5 stimulates Ca2+ mobilization in HEK293 cells expressing GPCR142 and Gα16. Overall, INSL5 behaves as an agonist for GPCR142 similar to relaxin-3. However, unlike relaxin-3, which is also a potent agonist for GPCR135 and LGR7, INSL5 does not activate either GPCR135 or LGR7. INSL5 inhibits 125I-relaxin-3 binding to GPCR135 with a low potency (Ki = 500 nm). A functional assay shows that INSL5 (1 μm) is a weak antagonist for GPCR135. In addition, INSL5 (up to 1 μm) shows no affinity or activity at LGR7 or LGR8 either in a binding assay or a bio-functional assay. Previously, we have demonstrated that GPCR142 mRNA is expressed in peripheral tissues, particularly in the colon. Here we show that INSL5 mRNA is expressed in many peripheral tissues, similar to GPCR142. The high affinity interaction between INSL5 and GPCR142 coupled with their co-evolution and partially overlapping tissue expression patterns strongly suggest that INSL5 is an endogenous ligand for GPCR142.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
